7th Annual Spring to Life Conference on Lung Cancer
- Describe current and evolving management strategies for patients with localized and locally advanced, non-small cell lung cancer.
- Identify best practices in biomarker testing and the utilization of biomarkers to drive treatment decisions for patients with lung cancer.
- Explain the application of targeted therapy and immunotherapy in the treatment of NSCLC.
- Outline the clinical trial data on the use of molecular drivers in the management of patients with advanced, non-small cell lung cancer.
- Summarize current and emerging strategies in the management of patients with advanced, non-small cell lung cancer without driver mutations.
WANT TO KNOW MORE?
The University of Chicago reserves the right to cancel or postpone this conference due to unforeseen circumstances. In the unlikely event this activity must be cancelled or postponed, the registration fee will be refunded; however, The University of Chicago is not responsible for any related costs, charges, or expenses to participants, including fees assessed by airline/travel/lodging agencies.
Medical Hematology and Oncology Director
NYOH Hematology Stem Cell Transplant Program
Clinical Assistant Professor
Albany Medical College
NYOH Albany Cancer Center
NYOH Albany Cancer Center
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME through the joint providership of The University of Chicago Pritzker School of Medicine and New York Oncology Hematology, PC, and in collaboration with MyMedEd, Inc.
The University Of Chicago Pritzker School Of Medicine designates this live activity for a maximum of 4.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.